Close Menu

NEW YORK (GenomeWeb) – Invivoscribe announced today that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the firm's LeukoStrat CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo's quizartinib for the treatment of FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML) patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.